DOLPHMED.BO · BSE
DOLPHIN MEDICAL SERVICES LTD.
₹7.83
+4.96% (+₹0.37)
Prev. close
₹7.46
Volume
54,106
As of
16 Nov 2026
Price history
Analyst sentiment
No analyst stances in this range
0 analyst stances · last 90 days · one per analyst
Try a wider range — no analyst has covered this yet.
Explore by date range →Analyst opinions
Fundamentals
About DOLPHIN MEDICAL SERVICES LTD.
Dolphin Medical Services Limited engages in the provision of diagnostics and other allied services in India. Dolphin Medical Services Limited was incorporated in 1992 and is based in Vijayawada, India.
Details
Sector
Healthcare
Industry
Diagnostics & Research
Headquarters
Vijayawada
Website
dolphinmedicalservices.comExchange
View on BSE ↗Key stats
Market cap
₹2.84 Cr
P/E ratio (TTM)
54.7
Dividend yield
0.00%
EPS (TTM)
₹0.13
Beta (1Y · daily vs NIFTY 50)
-0.09
Beta (5Y · monthly vs NIFTY 50)
0.10
Shares float
11.90 L
EPS · quarter ended Jun 2026
₹0.11
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
Total assets for FY22: from the company's own statements, which the series had none for. Current assets for FY22: from the company's own statements, which the series had none for. Equity for FY22: from the company's own statements, which the series had none for. Inventory for FY22: from the company's own statements, which the series had none for. Cash for FY22: from the company's own statements, which the series had none for.
08 · Profit & Loss — as filed
Annual
| Line item | FY23 | FY24 | FY25 |
|---|---|---|---|
| ₹64.80 L | ₹71.54 L | ₹81.63 L | |
Cost of materials consumed | ₹9.16 L | ₹11.07 L | ₹11.56 L |
Employee benefit expense | ₹7.19 L | ₹8.47 L | ₹6.60 L |
Financial Costs | ₹92,923 | ₹95,488.31 | ₹95,488.31 |
Depreciation and amortization expense | ₹6.27 L | ₹4.65 L | ₹6.27 L |
Other expenses | ₹53.01 L | ₹56.04 L | ₹59.27 L |
Total Expenses | ₹76.56 L | ₹81.18 L | ₹84.66 L |
3. Profit/(Loss) before exceptional items and tax | ₹-11.76 L | ₹-9.64 L | ₹-3.04 L |
4. Exceptional items | ₹0 | — | — |
5. Profit/(Loss) before tax | ₹-11.76 L | ₹-9.64 L | ₹-3.04 L |
| ₹69,708 | ₹76,365 | ₹34,374 | |
10. Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | ₹0 | — | — |
11. Net Profit/(Loss) for the period from continuing operations | ₹-12.46 L | ₹-10.40 L | ₹-3.38 L |
12. Profit/(loss) from discontinued operations before tax | ₹0 | — | — |
13. Tax expense of discontinued operations | ₹0 | — | — |
14. Net Profit/(loss) from discontinuing operations before tax | ₹0 | — | — |
15. Net profit/(Loss) for the period | ₹-12.46 L | ₹-10.40 L | ₹-3.38 L |
16. Other comprehensive income net of taxes | ₹0 | — | — |
17. Total Comprehensive Income/(Loss) for the period | ₹-12.46 L | ₹-10.40 L | ₹-3.38 L |
Basic earnings (loss) per share | 0.00 | -0.07 | -0.02 |
Diluted earnings (loss) per share | 0.00 | -0.07 | -0.02 |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
All years: standalone statements.
09 · Balance Sheet — as filed
Annual
| Line item | FY23 | FY24 | FY25 |
|---|---|---|---|
| ₹10.21 Cr | ₹10.16 Cr | ₹10.10 Cr | |
| ₹1.96 Cr | ₹1.97 Cr | ₹1.98 Cr | |
3 Non-current assets classified as held for sale | ₹0 | — | — |
| ₹12.17 Cr | ₹12.13 Cr | ₹12.08 Cr | |
| ₹10.18 Cr | ₹10.07 Cr | ₹10.04 Cr | |
| ₹1.34 Cr | ₹1.39 Cr | ₹1.46 Cr | |
| ₹65.78 L | ₹66.60 L | ₹57.62 L | |
Liabilities directly associated with assets in disposal group | ₹0 | — | — |
Regulatory deferral account credit balances and related deferred | ₹0 | — | — |
| ₹12.17 Cr | ₹12.13 Cr | ₹12.08 Cr |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
All years: standalone statements.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹-5 | ₹-4.50 L | ₹-5.97 L | ₹13.60 L | |
Investing cash flow | — | — | ₹0 | ₹0 | ₹0 | ₹-45.40 L |
| — | — | ₹5 | ₹4.78 L | ₹6.34 L | ₹31.32 L | |
Capital expenditure | — | — | — | — | — | ₹-45.40 L |
End cash position | — | — | ₹1.65 L | ₹1.65 L | ₹2.02 L | ₹1.54 L |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| DOLPHIN MEDICAL SERVICES LTD. | ₹2.84 Cr | ₹7.11 | 54.7 | 0.28 | 0.4% | 0.09 | -3.8% | +240.2% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Dolphin Medical Services Limited Reports Earnings Results for the Half Year Ended September 30, 2026
www.marketscreener.com · 8 days ago